Skip to Main Content

Veda Giri, MD

Professor of Internal Medicine (Medical Oncology); Division Chief, Clinical Cancer Genetics; Director, Cancer Genetics and Prevention Program; Director, Early Onset Cancer Program

Contact Information

Veda Giri, MD

Patient Care Location

Mailing Address

  • Yale School of Medicine

    333 Cedar Street WWW214A

    New Haven, CONNECTICUT 06520

    United States



Veda N. Giri, MD is a medical oncologist with specialization in clinical cancer genetics. Dr. Giri is Division Chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer Hospital and Assistant Director of Clinical Cancer Genetics for Yale Cancer Center, where she leads an integrated and comprehensive effort in cancer genetic evaluation to inform precision medicine, tailored cancer screening, and hereditary cancer risk. She is also Director of the Early Onset Cancer Program. In 2023 she was named a Fellow of the American Society of Clinical Oncology (FASCO).

Dr. Giri's research portfolio includes population science studies focused on genetic evaluation of cancer risk, disparities in access to genetic testing and genetic counseling, and implementation research. She has led numerous studies to advance the field of genetic counseling and genetic testing for inherited prostate cancer. Dr. Giri started the first Men’s Genetic Risk Clinic in the US in 2014 focused on genetic evaluation of inherited prostate cancer in the setting of multidisciplinary care. Dr. Giri also co-chaired the 2017 and 2019 Philadelphia Prostate Cancer Consensus Conferences that addressed development of comprehensive frameworks for genetic evaluation and implementation of genetic testing for prostate cancer. She is the Principal Investigator of multiple grant-funded prostate cancer genetic evaluation studies spanning genetic counseling, genetic testing, disparities, behavioral science, and implementation research. As leader of clinical cancer genetics, Dr. Giri plans to expand population science studies across cancer populations and in the community setting.

Dr. Giri received her medical degree from Sidney Kimmel Medical College (previously Jefferson Medical College) and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics and cancer risk assessment at Fox Chase Cancer Center. She also has a certification in cancer risk assessment from City of Hope Comprehensive Cancer Center. Dr. Giri currently serves on several national committees including the NIH PDQ® Cancer Genetics Editorial Board, ASCO Evidence-Based Medicine Committee, ASCO Cancer Care Delivery Council, ASCO Health Equity and Outcomes Committee, and ASCO Coverage and Reimbursement Steering Committee contributing expertise in cancer risk assessment and genetics at the national level.

Education & Training

  • MD
    Sidney Kimmel Medical College, Thomas Jefferson University
  • BS
    Pennsylvania State University-Six-year premedical-medical program, BS, Science (1993)

Honors & Recognition

AwardAwarding OrganizationDate
Fellow American Society of Clinical Oncology2023
Discovery of the Year Award in Population ScienceSidney Kimmel Cancer Center, Thomas Jefferson University2018
Society of ScholarsFox Chase Cancer Center2017
Mark Roth, MD Memorial Research AwardUniversity of Michigan2003
Hobart Amory Hare Honor Medical SocietySidney Kimmel Medical College, Thomas Jefferson University1996
Hobart Amory Hare Honor Medical SocietySidney Kimmel Medical College, Thomas Jefferson University1996

Professional Service

Journal of Clinical Oncology – Precision OncologyEditorial Board Member2022 - 2025
Prostate Cancer Foundation Young Investigator Grants Reviewer2022
ASCO Coverage & Reimbursement Steering GroupMember2021 - 2024
ASCO Cancer Care Delivery CouncilMember2021 - 2024
Journal of Clinical OncologyReviewer2021
Thomas Jefferson University Faculty Advisory CouncilMember2021 - Present
Faculty Advisory CouncilMember2021 - Present
ASCO Health Equity and Outcomes CommitteeMember2020 - 2023
Prostate Cancer Foundation Young Investigator Grants Reviewer2020 - 2022
NCI Clinical and Translational R21 and Omnibus R03 Review PanelReviewer2020
Committee on Student PromotionMember2020 - Present
ASCO Genetics SubcommitteeMember2020 - Present
Chair-Elect 2022-2023, ASCO Evidence Based Medicine CommitteeMember2019 - 2024
Frontiers in Oncology and Frontiers in GeneticsAssociate Editor2019 - 2020
Cancer Center Review Committee for ACS IRG GrantsMember2019
Medical Oncology Mentoring CommitteeMember2019 - Present
Center for Scientific Review (CSR)Early Career Reviewer (ECR) program at the Center for Scientific Review (CSR), NIH2018
NCI Special Emphasis Panel Reviewer2018 - Present
Education CommitteeMember2017 - 2019
Track LeaderMember2017 - 2019
ASCO Cancer Prevention, Hereditary Genetics, and Epidemiology CommitteeMember2017 - 2018
Scientific Advisory Faculty Forum, Thomas Jefferson Member2017 - Present
Transdisciplinary Integration of Population Science (TIPSLead2016 - 2020
Leadership CouncilMember2016 - 2018
NIH Cancer Biomarkers Study SectionReviewer2015
NIH Special Emphasis Panel Reviewer2015
NCI EDRN Review PanelReviewer2015 - Present
NIH Cancer Biomarkers Study SectionReviewer2013
Special Issue of Prostate Cancer: “Prostate Cancer in Developing Countries”Guest Editor2012
Open Access Journal of Urology Editorial Board Member2008
American Society of Clinical OncologyMember2001 - Present

Departments & Organizations